IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Biocon and Optimer Sign API Manufacturing Deal

11:08 PM MDT | May 25, 2010 | Deepti Ramesh

Biotechnology company and manufacturing services provider Biocon (Bangalore, India) says it has entered into a long-term supply agreement with biopharmaceutical company Optimer Pharmaceuticals (San Diego, CA) for the commercial manufacturing of the active pharmaceutical ingredient (API) fidaxomicin - Optimer's lead product candidate for the treatment of clostridium difficile infection (CDI). Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of CDI and Optimer has reported positive top-line results from two Phase 3 trials of...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa